Eli Lilly and Company is a U.S.-based pharmaceutical company headquartered in Indianapolis, Indiana. Founded in the late 19th century by chemist Eli Lilly, the company operates within the Health Care sector, primarily in the pharmaceuticals industry.

Lilly focuses on the research, development, and commercialization of prescription medicines targeting chronic and complex diseases. Its therapeutic areas include:

• Diabetes and Metabolic Disorders: Including insulin therapies and treatments for type 2 diabetes and related metabolic conditions.

• Oncology: Medicines for various types of cancer across solid tumors and hematologic conditions.

• Neuroscience: Treatments for neurological and psychiatric disorders, including neurodegenerative diseases.

• Immunology: Therapies for autoimmune conditions such as rheumatoid arthritis and psoriasis.

The company operates globally, serving patients in more than 100 countries through research facilities, manufacturing sites, and commercial operations worldwide. Lilly follows a research-intensive business model, allocating substantial resources to research and development to support innovation and long-term pipeline growth.

Strategic collaborations with biotechnology firms, research institutions, and healthcare partners further support the advancement of new therapeutic solutions. Eli Lilly’s shares are traded on the New York Stock Exchange under the ticker LLY.

History and Development

Eli Lilly and Company was founded with the objective of producing high-quality, scientifically formulated medicines at a time when pharmaceutical standards were inconsistent. Early adoption of standardized manufacturing practices helped establish the company’s reputation for reliability and innovation.

Over time, Lilly expanded its product portfolio and became a major participant in key therapeutic breakthroughs, including the commercialization of insulin and the development of treatments for psychiatric and cardiovascular conditions.

The company later strengthened its focus on biotechnology-driven drug development, broadening its presence in oncology, immunology, and neuroscience.

In recent years, Eli Lilly has intensified investment in metabolic disease treatments, oncology therapies, and neurodegenerative research, while advancing its pipeline through both internal development and strategic acquisitions.

Today, Eli Lilly is recognized as one of the leading global pharmaceutical companies, with a strong emphasis on scientific research, innovation, and long-term therapeutic advancement.

Additional Information

Eli Lilly and Compay (United States) is listed on the NYSE and has a market capitalization of $1.13 trillion, with shareholders equity totaling $33.88 billion.

The company employs approximately 35.000 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Eli Lilly and Compay reported $79.67 billion in revenue, generating net income of $26.71 billion.

Key financial metrics include a P/E ratio of 42.15, a price-to-book (P/B) ratio of 33.23, and a trailing twelve-month dividend yield of 0.51%.

The company trades under the ticker LLY.